EyePoint Overview
- Year Founded
-
1987
- Status
-
Public
- Employees
-
214
- Stock Symbol
-
EYPT
- Investments
-
3
- Share Price
-
$0.23
- (As of Friday Closing)
EyePoint General Information
Description
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Contact Information
Website
www.eyepoint.bioCorporate Office
- 480 Pleasant Street
- Suite C-400
- Watertown, MA 02472
- United States
Corporate Office
- 480 Pleasant Street
- Suite C-400
- Watertown, MA 02472
- United States
EyePoint Stock Performance
As of 20-Nov-2026, EyePoint’s stock price is $0.23. Its current market cap is $26.6M with 114M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.23 | $0.26 | $0.23 - $19.11 | $26.6M | 114M | 8.37M | -$3.96 |
EyePoint Financials Summary
As of 30-Sep-2026, EyePoint has a trailing 12-month revenue of $2.58M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 121,256 | 1,329,802 | 276,599 | 998,897 |
| Revenue | 2,579 | 31,371 | 43,273 | 46,018 |
| EBITDA | (349,039) | (241,125) | (144,314) | (75,914) |
| Net Income | (342,523) | (231,962) | (130,870) | (70,795) |
| Total Assets | 166,137 | 363,996 | 418,465 | 355,184 |
| Total Debt | 19,124 | 20,772 | 21,858 | 4,906 |
EyePoint Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
EyePoint Comparisons
Industry
Financing
Details
EyePoint Competitors (56)
One of EyePoint’s 56 competitors is BioMarin Pharmaceutical, a Formerly PE-Backed company based in San Rafael, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| Foventa Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| The Zambon Group | Private Debt Financed | Bresso, Italy | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| PulseSight Therapeutics | Venture Capital-Backed | Paris, France |
EyePoint Signals
EyePoint Investments & Acquisitions (3)
EyePoint’s most recent deal was a Corporate Asset Purchase with Aerpio Pharmaceuticals (Razuprotafib Patents and Patent Applications) for . The deal was made on 17-Aug-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aerpio Pharmaceuticals (Razuprotafib Patents and Patent Applications) | 17-Aug-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Icon Bioscience | 28-Mar-2018 | Merger/Acquisition | Drug Delivery | ||
| Control Delivery Systems | 30-Dec-2005 | Merger/Acquisition | Drug Delivery |
EyePoint ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.2 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
EyePoint FAQs
-
When was EyePoint founded?
EyePoint was founded in 1987.
-
Where is EyePoint headquartered?
EyePoint is headquartered in Watertown, MA.
-
What is the size of EyePoint?
EyePoint has 214 total employees.
-
What industry is EyePoint in?
EyePoint’s primary industry is Drug Discovery.
-
Is EyePoint a private or public company?
EyePoint is a Public company.
-
What is EyePoint’s stock symbol?
The ticker symbol for EyePoint is EYPT.
-
What is the current stock price of EyePoint?
As of 20-Nov-2026 the stock price of EyePoint is $0.23.
-
What is the current market cap of EyePoint?
The current market capitalization of EyePoint is $26.6M.
-
What is EyePoint’s current revenue?
The trailing twelve month revenue for EyePoint is $2.58M.
-
Who are EyePoint’s competitors?
BioMarin Pharmaceutical, Foventa Therapeutics, The Zambon Group, Voyager Therapeutics, and PulseSight Therapeutics are some of the 56 competitors of EyePoint.
-
What is EyePoint’s annual earnings per share (EPS)?
EyePoint’s EPS for 12 months was -$3.96.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process